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Chronic Mouse Model of TMA-Induced Contact
Hypersensitivity
Claudia Schneider1, Wolf-Dietrich F. Do¨cke1, Thomas M. Zollner1 and Lars Ro¨se1
Due to the steadily increasing incidence of atopic dermatitis (AD), especially in children, there is a high medical
need for new therapies and improved animal models. In mice, trimellitic anhydride (TMA) is routinely used to
trigger T-cell-dependent contact hypersensitivity (CHS) reactions. In this study, we compared the standard
acute TMA-induced CHS in Balb/c mice with subacute and chronic models of TMA-induced ear inflammation.
Compared to the acute model, the chronic CHS model more closely reflects characteristics of AD, such as
typical morphological changes of the inflamed skin, strong infiltration with T cells, major histocompatibility
complex II-positive cells, eosinophils, and mast cells, a T-helper cell-type (Th) 2 cytokine profile and a
strong increase of serum IgE levels. Moreover, a strong lymph node involvement with T-helper cell dominance
and a mixed Th1/Th2 T-cell differentiation and activation pattern was demonstrated. Importantly, as
demonstrated by successful therapy with prednisolone, the chronic TMA-induced CHS model, in contrast
to acute and subacute models, made prolonged therapeutic treatment of a pre-established skin inflammation
possible. Altogether, we present an improved model of mouse T-cell-dependent skin inflammation for AD.
We hope this model will enhance the predictive value of animal models for therapeutic treatment of
atopic eczema.
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INTRODUCTION
In recent years, the prevalence of atopic dermatitis (AD) in
industrialized countries has greatly increased, up to approxi-
mately 20% in infants (Homey et al., 2006). AD is a common
pruritic and chronically relapsing inflammatory skin disease
that is associated with genetic predisposition, cutaneous
hyperreactivity to environmental triggers, and immune
dysregulation (Homey et al., 2006). Despite increasing
characterization of AD, a complete understanding of the
disease is still evolving, calling for improved animal models
that will lead to needed new therapies. An elucidative animal
disease model should evaluate crucial features of disease
pathogenesis and allow evaluation of previously unknown
therapeutic concepts. A suitable animal model for AD has to
reflect the multiple facets of the human disease with regard to
the typical macroscopic and microscopic skin morphology,
involved immune cell subsets (e.g. T-helper cells, eosino-
phils, mast cells), a Th2 cytokine secretion profile, IgE
enhancement, induction by environmental factors, and a
chronic etiopathology. Furthermore, it should be inexpen-
sive, fast, and easy to handle, and allow high throughput.
Numerous mouse models have been proposed for AD and
used to study pathological aspects of the disease (Matsuda
et al., 1997; Chan et al., 2001; Dearman et al., 2002). Mice
spontaneously developing AD-like lesions are of particular
interest. The NC/Nga mouse strain spontaneously develops
AD-like eczematous skin lesions and shows typical clinical
and immunological findings of AD: increase of IgE levels,
CD4þ T-cell infiltration as well as Th2 cytokine production
(Matsuda et al., 1997). The development of AD-like lesions
under nonsterile (conventional) conditions demonstrates the
influence of environmental factors similar to the human
disease, but the antigens and their effects are unknown. In
addition to antigens, skin barrier function has an important
role with regard to allergic risk (Hudson, 2006). Genetic
factors such as fillagrin mutations (Palmer et al., 2006),
physical, chemical, and enzymatic activities of certain factors
such as Der P 1 may pave the way for allergens to penetrate
subepidermal layers to get in contact with antigen-presenting
cells. Moreover, mice that are transgenic under K14 promoter
for IL-4 (Chan et al., 2001) or IL-18 (Konishi et al., 2002) and
mice that overexpress the Th2 cytokines IL-4, IL-5, and IL-13
regulated by Th2 locus control region (Lee and Flavell, 2004)
have been described to develop spontaneous AD-like skin
disease. Indeed, these animal models resemble the human
disease, but their utilization is hindered due to limited
availability, lack of schedule variation, inconsistent reprodu-
cibility, long prodromal phase of onset (8–17 weeks in NC/
Nga, several months in K14-IL-4 transgenic mice), and
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difficult evaluation of skin lesion severity (Shiohara et al.,
2004).
In contrast to transgenic mice, hapten- and allergen-induced
contact hypersensitivity (CHS) animal models are simple and
highly reproducible. Widely available inbred mouse strains are
commonly used where CHS is induced by topical exposure of
presensitized mice with haptens such as dinitrofluorobenzene,
2,4-dinitrochlorobenzene, and trinitrochlorobenzene or aller-
gens such as trimellitic anhydride (TMA). These animal models
might reflect various types of inflammation utilizing different
haptens/allergens and mouse strains.
Trimellitic anhydride, a known respiratory sensitizer
(Bernstein et al., 1982), is often used to trigger T-cell-
dependent CHS reactions in mice and elicits eosinophil and
T-cell infiltration, Th2 cytokine production, and IgE increase.
In TMA-induced CHS models, mice are sensitized on flank
skin and T-cell-dependent skin inflammation is induced by
topical challenges of ears. Thus, the severity of inflammation
can easily be evaluated by ear thickness measurements. The
effects of TMA-induced inflammation on cutaneous cytokine
profile, immune cell infiltration, and serum IgE levels have
been intensively studied (Dearman et al., 2002; Sailstad et al.,
2003). Dearman et al. (2002) used a schedule with two TMA
sensitizations (days 0 and 5) and three challenges (days 10,
11, 12) to analyze the cytokine fingerprinting of chemical
allergens. They showed that corresponding lymph node cells
derived from TMA-treated Balb/c mice expressed high levels
of the Th2 cytokines IL-4 and IL-10, but little of the Th1
cytokine IFNg; exposure to 2,4-dinitrochlorobenzene pro-
voked the inverse pattern of cytokine secretion (Dearman
et al., 1996, 2002).
Previously described mouse models of AD are well
characterized and reflect some important clinical character-
istics of AD. However, there is a high need to develop new
nontransgenic allergen-induced CHS models that create a
Th2-polarized chronic skin inflammation that can be utilized
for therapeutic treatment.
We investigated the influence of repeated TMA challenges
on characteristics of skin inflammation and immunopheno-
type of draining auricular lymph nodes as well as the effect of
prophylactic and/or therapeutic treatment with the standard
glucocorticoid prednisolone. The goal was to establish a
chronic mouse model for AD reflecting the chronic human
disease with reliable corresponding readouts: characteristics
of inflamed skin morphology on a stable non-necrotic
plateau, pronounced cutaneous infiltration with T cells,
macrophages, eosinophils and mast cells, characteristic Th2
cytokine pattern in skin, increased serum IgE levels, and a
significant involvement of corresponding lymph nodes.
RESULTS
Kinetics of ear thickness and treatment response to
prednisolone in TMA-induced CHS models
Trimellitic anhydride triggered an increase of ear thickness in
CHS models in Balb/c mice that was used for kinetic
assessment of inflammation establishment as well as treat-
ment response to prednisolone (30mg kg1 per os). In all
three models—acute, subacute and chronic—a 5% TMA
challenge induced a significant increase in ear thickness from
about 0.2 to 0.4mm on day 6 post-immunization (Figure 1a).
In the acute TMA-induced CHS model, prophylactic treat-
ment with prednisolone at 1 hour before challenge inhibited
ear thickness formation by 56%. In the subacute model, three
consecutive 5% TMA challenges led to a cumulative increase
of ear thickness. The partially prophylactic treatment with
prednisolone (daily at 1 hour before challenge) significantly
inhibited ear thickness increase by 50%. In the chronic TMA-
induced CHS model, stable, non-necrotic inflammation
plateauing at 0.4–0.5mm ear thickness was established after
an initial 5% TMA challenge (day 5) and subsequent daily
low-dose challenges with 2% TMA. From days 9 to 14, daily
therapeutic prednisolone treatment was performed that led to
an incremental decline in ear thickness and a therapeutic
response of 68% inhibition of skin inflammation on day 15.
Strong granulocyte infiltration with superior therapeutic
response in chronic TMA-induced CHS model
Cutaneous infiltration of granulocytes was assessed by
determining myeloperoxidase activity in ear homogenates
(Figure 1b). Activity of myeloperoxidase, stored in granules of
granulocytes, is a confident marker of granulocyte infiltration
and activity in the skin. In all models, high peroxidase activity
and significant treatment response to prednisolone were
detected. The most significant response was observed in the
chronic TMA-induced CHS model (75%).
Increased serum IgE level in chronic TMA-induced CHS model
Serum IgE, which is enhanced in most AD patients (Hoffmann
et al., 1975), was determined in TMA-induced CHS models
as a parameter for the humoral response in Th2 conditions.
We observed no or only minor IgE induction at the
termination time points of the acute and subacute TMA-
induced CHS models on days 6 and 8, respectively (Figure
1c). In contrast, in the chronic model (day 15), a strong
increase of systemic IgE levels was demonstrated. This
parameter, however, was not suitable for monitoring the
anti-inflammatory potential of prednisolone therapy in the
chronic TMA-induced CHS model. Rather, prednisolone
resulted in some induction of IgE serum levels after 6 daily
therapeutic administrations reflecting the known IgE support-
ing activity of glucocorticoids.
Strongest cutaneous cell infiltration in chronic TMA-induced
CHS model
Morphological changes of inflamed skin and cutaneous cell
infiltration were characterized by histology and immunohis-
tochemistry. Strongest cell infiltration and acanthosis were
observed in the chronic TMA-induced CHS model (Figure 2a,
hematoxylin and eosin staining). Persistence of eosinophils in
dermis was confirmed by hematoxylin and eosin staining for
all three TMA models (see enlarged example for chronic
model in the lower left corner Figure 2a) but not for the
respective solvent groups. When determining eosinophil
peroxidase activity in ear homogenates by using the specific
substrate o-phenylenediamine (Tsunematsu et al., 2007), we
found strong increases in the TMA groups in comparison to
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solvent controls (activity o1.5 arbitrary units (AU)) and in
tendency highest values in the chronic TMA-induced CHS
model (chronic: 10.3±4.8AU, subchronic: 9.1±2.2AU,
acute: 7.7±0.5AU; n¼ 10). Mast cells (toluidine blue
staining) were demonstrated in the dermis in all three models,
but highest number is seen in the chronic TMA-induced CHS
model (Figure 2b). Dermal infiltration with major histocompat-
ibility complex II (MHCII)-positive cells is found in all three
models but is more pronounced in subacute and chronic than
in acute TMA-induced CHS model (Figure 2c).
Cutaneous T-cell infiltration was visualized by immuno-
histochemistry using antibodies to CD4 and CD8 (Figure 2d
and e, respectively). Although T-cell infiltration is rather weak
in the acute TMA-induced CHS model, it is stronger in the
subacute model and strongest in the chronic model. Similar
to the infiltration pattern in atopic eczematic lesions, CD4þ
T-helper cell infiltrates were predominantly observed in the
dermis (Figure 2d) whereas CD8þ T cells were mainly
localized in the epidermis (Figure 2e).
Cutaneous type 2-polarized cytokine profile in chronic
TMA-induced CHS model
To characterize the cutaneous cytokine pattern in acute,
subacute, and chronic TMA-induced CHS models in Balb/c
mice, cytokine expression in ears was determined on mRNA
and protein levels by quantitative RT-PCR and multiplex
protein analysis in ear homogenates (MesoScale, Gaithers-
burg, MD), respectively. IL-5, IL-10, and IL-12p40 were not
detectable at protein or mRNA level in any of the models.
Each TMA-induced CHS model demonstrated an unique
cutaneous cytokine profile (Figure 3). The Th1 cytokine,
IFNg, was detectable at the protein level in acute inflamma-
tion, but without treatment response to prednisolone (Figure
3a). The subacute and chronic models exhibited very low
IFNg protein levels. The Th2 cytokine, IL-4, showed the most
significant increase as well as the strongest treatment
response in the chronic TMA-induced CHS model. On
mRNA level IFNg and IL-4 were not detected.
As IFNg and IL-4 were not detectable on mRNA level, we
additionally investigated the mRNA expression of the type 1
cytokine and IFNg inducer IL-12 (IL-12p35) and of the Th2
cytokine IL-13. All models demonstrated a significant
increase in IL-12p35, reaching a maximum in the subacute
model. IL-13 mRNA expression was clearly increased in
subacute and chronic TMA-induced CHS models compared
to a weak induction in the acute model resembling the
protein pattern for IL-4. Although IL-12p35 expression was
decreased by prednisolone treatment, no response was
observed for IL-13.
The proinflammatory cytokine IL-1b was detected in all
TMA-induced CHS models (Figure 3b). Protein data showed
an incremental increase of IL-1b with model prolongation. In
contrast to subacute model, where prednisolone did not
suppress IL-1b generation, in the acute and chronic models, a
clear treatment response was observed.
Tumor necrosis factor-a is highly transcribed and synthe-
sized (Figure 3b) in the subacute TMA-induced CHS model.
Although only a small treatment response was seen at mRNA
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Figure 1. Inflammation parameters in acute, subacute, and chronic TMA-induced mouse CHS models. Acute (A), subacute (SA), and chronic (C) TMA-induced
CHS models were executed as described in the Materials and Methods. (a) Ear thickness (n¼ 11), (b) activity of myeloperoxidase (n¼ 5), (c) serum IgE levels
(n¼10), and (d) weight of auricular lymph nodes (n¼11) are shown as mean±SD. Percentage values for inhibition of inflammation parameters at the end
of experiment are given at 24 hours either after single prednisolone application (day 5) for acute model, after three applications (days 5–7) for subacute model, or
after six daily doses of 30mg kg1 prednisolone (days 9–14) in chronic model. **Po0.01, ***Po0.001 TMA group compared with solvent group; þPo0.05,
þ þPo0.01, þ þ þPo0.001, treatment group compared with TMA group; #Po0.05, ###Po0.001, comparison of TMA groups among the three models.
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level, significant inhibition by prednisolone was found on
TNFa protein level indicating posttranscriptional regulation.
In acute and chronic TMA-induced CHS models, a smaller
increase of TNFa was detected on protein level and a
treatment response was demonstrated.
Strongest lymph node reaction in chronic TMA-induced CHS
model
In response to allergen-induced CHS, lymph node cell
proliferation and immune cell infiltration cause auricular
lymph node weight increase. Only a slight weight gain was
found in the acute TMA-induced CHS model. A stronger
increase was observed in the subacute model, and the
strongest increase was found in the chronic model (Figures 1d
and 4a). Significant inhibition of weight increase by
prednisolone treatment was observed in subacute and
chronic TMA-induced CHS models (Figure 1d).
The expression of the inflammatory cytokines TNFa and
IL-1b as well of Langerin as indicator for skin inflammation-
triggered Langerhans cell homing in the auricular lymph
nodes is strongest in acute model and incrementally declines
in the subacute and chronic TMA-induced CHS models
(Figure 4b).
Because of the strong interindividual and intergroup
variation of CD3d expression as parameter for T cells (Figure
4b), the gene expression of lymphokines and T-cell transcrip-
tion factors was analyzed as fold expression of CD3d (Figure
4c). Remarkably, the strongest relative expression of IL-4 as
well as of the Th2-typifying transcription factor, GATA-3, in
auricular lymph nodes was demonstrated in chronic TMA-
induced CHS model that also exhibits the strongest cutaneous
Th2 cytokine expression (see Figure 3). Furthermore, a high
IFNgmRNA expression in lymph nodes from acute model ran
in parallel to the increased IFNg protein expression in skin
but was not accompanied by an increased T-bet expression.
Therefore, it might rather reflect a strong proinflammatory
response (as also indicated by the strong expression of
inflammatory cytokines in auricular lymph nodes) than a type
Acute solvent Acute model Subacute model Chronic model
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b
c
d
e
Figure 2. Cutaneous cell infiltration in acute, subacute, and chronic TMA-induced mouse CHS models. Skin from acute solvent control as well as acute,
subacute, and chronic TMA-induced ear inflammation models was stained by HE (a), toluidine blue (b) and antibodies against MHCII (I-Ad; c), CD4 (d), and CD8
(e). In the acute TMA-induced CHS model, only a weak infiltration by eosinophils, mast cells, MHCII-, CD4-, and CD8-positive cells is seen. Stronger cell
infiltration is visible in subacute model. Strongest immune cell infiltration as well as acanthosis is seen in the chronic TMA-induced CHS model. Although CD8þ
cells are predominantly found in the epidermis, CD4þ T-helper cells are mainly located in the thickened dermis of the dorsum of the ears. For eosinophils and
mast cells in chronic model also see the inserts in (a) and (b), respectively. Scale bar¼ 100mm.
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1 T-cell differentiation pattern. In chronic TMA-induced CHS
model, however, both parameters, IFNg and T-bet, were
highly expressed in lymph nodes indicating a marked type 1
T-cell differentiation.
Finally, we investigated the T cells in auricular lymph
nodes using flow cytometry (Figure 4d). Interestingly,
progressively increasing CD4þ /CD4 T-cell ratios were
observed in subacute and chronic models indicating a
T-helper cell-triggered inflammation. Moreover, the expres-
sion of the early activation antigen, CD69 (CLEC2C), which
might be triggered by cytokines independently from T-cell
receptor stimulation (Vilanova et al., 1996; Kranzer et al.,
2000), was highest in the chronic model on both, CD4þ and
CD4 T-cell populations. In contrast, the expression of CD25
(IL-2R-a), MHCII (I-Ad) and CD49d (Itga4), representing T-cell
activation antigens that depend on T-cell receptor activation
and proliferation, was lower in chronic and subacute models
than in the acute TMA-induced CHS model. The expression
of CD45RB and CD62L (L-selectin) showed no consistent
regulation except a decrease of L-selectin expression in
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subacute in comparison to acute TMA-induced CHS model
(Figure 4d).
Together these data hint to a predominantly T-helper cell-
and cytokine-driven inflammation and a mixed T-cell
differentiation pattern in the draining lymph nodes from
chronic TMA-induced CHS model as it is also described for
lesional skin in chronic AD (Grewe et al., 1998).
DISCUSSION
We have established to our knowledge previously unreported
subacute and chronic TMA-induced T-cell-dependent skin
inflammation models in Balb/c mice. Remarkably, only the
chronic TMA-induced CHS model quite closely reflects
characteristics of AD such as increased systemic IgE levels,
altered skin morphology, strong cutaneous immune cell
infiltration, Th2 cytokine profile in the skin, as well as a
mixed type 1/2 T-cell differentiation pattern in the draining
lymph nodes. Thus, the chronic TMA-induced CHS model
shows increased correlation to the clinical situation and is
presumed to have an enhanced predictivity for AD.
The acute TMA-induced CHS model may have an
advantage particularly for early-stage drug discovery because
of its short-time schedule (6 days) and the subsequent rapid
data accumulation regarding anti-inflammatory potential of
new compounds. However, this model, despite some
increase in cutaneous IL-4 levels, rather represents an acute
Th1-dominated inflammation even in the Th2-prone Balb/c
mice and also lacks several other features of the AD disease
phenotype such as increase in systemic IgE levels. Moreover,
only short-term, prophylactic treatment is possible. Therefore,
the acute TMA-induced CHS model likely has a very limited
predictivity for AD.
For each model, total IgE levels in sera were determined at
the end of the schedule (d6, d8, and d15, respectively). Other
groups use d14 as readout for IgE serum levels also in acute
TMA-induced CHS model in mice (Guo et al., 2002).
Moreover, IgE kinetics after TMA exposure in sensitized
Brown Norway rats demonstrated maximum IgE levels as late
as on d35 after single TMA challenge (Warbrick et al., 2002).
Thus, the readout on d6 and d8 in acute and subacute models
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likely underestimates the role of IgE after single or triple TMA
challenges.
The subacute CHS model with 3 daily 5% TMA challenges
exhibits a mixed cutaneous cytokine profile with enhanced
IL-4, IL-13, and IL-12p35 expression as well as very strongly
increased expression of the proinflammatory cytokines, TNFa
and IL-1b. It shows a more pronounced T-cell infiltration,
stronger involvement of draining lymph nodes, and an
increase in serum IgE levels. As also shown by the limited
activity of prednisolone treatment (50% inhibition of of ear
thickness), this model, in the setting used by us, represents a
quite exacerbated inflammation and, therefore, might be
more suitable for testing of compounds for the treatment of
acute AD exacerbation.
Hayashi et al. (2001) and Dearman et al. (2002) used
comparable subacute TMA challenge schedules to analyze
the kinetics of cytokine mRNA induction and the mitogen-
induced cytokine secretion profile in corresponding lymph
nodes. Both groups, however, did not analyze the cytokine
expression pattern in skin as well as the effect of anti-
inflammatory treatment on inflammation parameters as we
have presented here.
Taken together, though the acute and subacute
TMA-induced CHS models are commonly used in drug
discovery, they have deficits in regard to reflect the
immunopathogenesis of AD and to use treatment in a
therapeutic manner.
In our chronic TMA-induced CHS model, we demonstrated
that prolonged low-dose (2%) TMA exposure allows formation
of a stable skin inflammation, displayed as a plateau of ear
thickness, which is highly responsive to therapeutic treatment
by prednisolone. Moreover, mice in our chronic TMA-induced
CHS model exhibit the typical macroscopic skin appearance of
eczematous rash such as pruritus, erythematous hues, edema,
crusting, as well as excoriation (Abramovits et al., 2003) and
typical microscopic appearance of skin lesions such as
acanthosis (Simon et al., 2004).
Furthermore, the chronic TMA-induced CHS model is
characterized by a strong cutaneous infiltration with T cells
and MHCII-positive antigen-presenting cells as well as
involvement of dermal eosinophils and mast cells as it is
also known for atopic eczema (Ja¨rvikallio et al., 1997; Ou
and Huang, 2007). As cutaneous T-cell infiltration is of major
pathophysiological importance for AD, the pronounced skin
infiltration in the chronic TMA-induced CHS is a great
advance for the likely predictive value of the model.
Remarkably, we observed a strong CD4þ T-cell infiltration
in the dermis and a CD8þ cell infiltration mainly in the
epidermis of inflamed skin as it is known for the human
situation in AD (Lugovic et al., 2005).
For evaluation especially of the chronic TMA-induced
CHS model it has to be considered that the repeated use of an
acetone-containing solvent damages the skin barrier possibly
leading to enhanced exposure to environmental allergens
(Hudson, 2006). Importantly, however, in our model TMA as
a contact sensitizer was crucial to elicit T-cell infiltration. So,
even chronic treatment with the solvent alone did not trigger
substantial cutaneous T-cell infiltration (data not shown).
The three TMA-induced CHS models in Balb/c mice differ
in several inflammation parameters, but particularly each
model shows an unique cytokine profile, which might be
used to reflect specific phases of atopic eczema. AD develops
in an amplification cycle of atopic skin inflammation,
described as the itch–scratch cycle, which is mainly cytokine
driven (Homey et al., 2006). A strong pruritus, the most
cumbersome symptom of AD, results in mechanical injury
caused by scratching, and leads to the release of proin-
flammatory cytokines (Wood et al., 1992). This early stage of
AD is reflected in our subacute TMA-induced CHS model
where induction of inflammation over 3 days caused pruritus
(excoriated ears) and a strong increase of cutaneous IL-1b and
TNFa.
Although chronic AD lesions show either the coexistence
of both IL-4-producing Th2 and IFNg-producing Th1 cells or
even a type 1 cytokine dominance (Grewe et al., 1998), our
chronic TMA-induced mouse CHS model mainly exhibits a
Th2-dominant response in the skin as demonstrated by high
IL-4 and IL-13 and low IFNg and IL-12p35 expression. These
characteristics suggest an improved relevance for acute AD
lesions, which also exhibit strong IL-4 and IL-13 expression
(Tazawa et al., 2004).
Interestingly, however, the chronic TMA-induced CHS
model, in contrast to the more acute models, exhibits a mixed
type 1/2 T-cell differentiation and activation pattern in
auricular lymph nodes. Moreover, an increased proportion
of CD4þ T cells and the preferential expression of the
cytokine-dependent activation antigen, CD69 (Vilanova
et al., 1996; Kranzer et al., 2000), on T cells in auricular
lymph nodes hint to a T-helper cell-driven chronic inflam-
mation. From this, it might be hypothesized that further
prolongation of TMA exposure could possibly lead to a skin
immunophenotype more closely resembling the chronic AD
lesions including the increase of type 1 cytokines, IL-12 and IFNg.
Though further characterization is absolutely desirable,
with chronic TMA-induced CHS, we established a mouse
model for persisting skin inflammation caused by cutaneous
hyperreactivity to the respiratory allergen TMA, which might
quite adequately reflect the situation in AD patients who
frequently experience continuous exposure to environmental
allergens that repeatedly trigger allergic reactions and
contribute to the persistence of the disease (Leung, 1998).
The increased chronic character of the allergen-induced skin
lesions is associated with typical microscopic and macro-
scopic characteristics of lesional skin in AD. Moreover, as we
could demonstrate the chronic TMA-induced CHS model is
highly sensitive to therapeutic treatment of a preestablished
inflammation with prednisolone in a standardized setting. In
addition to the likely increased relevance for the clinical
situation, our animal model is inexpensive, reproducible,
fast, and easy to handle.
Taken together our chronic TMA model in Balb/c mice is
to our knowledge a previously unreported allergen-induced
CHS model that reflects the most important characteristics of
AD and allows prolonged therapeutic anti-inflammatory
treatment. We ascertain this model will have a high
predictive value for early drug discovery.
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MATERIALS AND METHODS
Animals
Female Balb/c mice (16–18 g; Charles River, Germany) were used
throughout the studies. Mice were housed according to institutional
guidelines with access to food (pelleted diet) and water ad libitum.
Animals (5–11) were randomly allocated to each experimental
group. Animal experiments have been approved by the govern-
mental administration of Berlin (Berlin, Germany).
Chemicals and drugs
Trimellitic anhydride (97%) was obtained from Sigma (Deisenhofen,
Germany) and dissolved in acetone and isopropylmyristate (4:1, v/v)
immediately before application. Prednisolone (Sigma) was dissolved
in dimethylsulfoxide (Merck, Germany), ethanol (96%; Sigma), and
peanut oil (5:3:92, v/v/v).
Schedules for mice sensitization, challenges and prednisolone
treatment
Mice were sensitized with 50ml 5% TMA on the shaved flank skin on
day 0. Challenges with 10ml 5% TMA on the dorsum of both ears were
performed on day 5 (acute model), and on days 5, 6, and 7 (subacute
model). In the chronic model, animals received 5% TMA on day 5 and
challenges with 2% TMA on the ears on days 6–14). In each model, a
solvent control group was exposed to acetone and isopropylmyristate
(4:1, v/v) throughout the duration of the experiment. In treatment
groups, 30mgkg1 prednisolone was given orally 1hour before
challenges. In acute and subacute models, mice were treated before
every challenge. In the chronic model, prednisolone treatment was
performed on days 9–14. Ear thickness over the time course was
determined with a custom-built micrometer (Schering AG, Germany).
Determination of immune mediators
Ears were mechanically homogenized in 2ml homogenization buffer
(hexadecyltrimethylic ammonium bromide/morpholinopropan sul-
fonic acid, Sigma), centrifuged at 25,000g for 20minutes at 12 1C,
and supernatant was used for determination of immunomediators.
Cutaneous granulocyte infiltration was assessed by myeloperoxidase
activity assay in ear homogenates as we recently described
(Schottelius et al., 2002).
Eosinophil infiltration was characterized by determining eosino-
phil peroxidase activity in ear homogenates using the specific
substrate, o-phenylenediamine, as described by Tsunematsu et al.
(2007). Eosinophil peroxidase activity is given as AU defined as OD
at 450 nm*25.
Cytokine levels in ear homogenates were determined using a
multiplex chemiluminescence method and MesoScale SI 6000
equipment (MesoScale Discovery). IgE concentrations in sera were
measured by ELISA (BD Bioscience, Germany).
RNA isolation from skin and quantitative real-time RT-PCR
analyses
RNA from skin specimens (ears) and auricular lymph nodes was
extracted and purified using a RNeasy Mini-Kit (Qiagen, Germany).
Purified RNA was qualified and quantified with the Agilent
Bioanalyzer 2100 system with RNA 6000 Nano Assay Kit (Agilent
Technologies, Germany). cDNA was synthesized using Reverse
Transcription Reagents and GeneAmp PCR System 9700 (Applied
Biosystems, Germany). RT–PCR of cDNA was performed on a 7900
HT Sequence Detection System (Applied Biosystems) under the
thermal conditions: 10minutes 95 1C, 40 cycles, 15 seconds 95 1C,
and 1minute 60 1C. The following genes were analyzed using Assays
on Demand from Applied Biosystems: HPRT as a housekeeping
gene (Mm00443258_m1), CD3d (Mm 00442746_m1), GATA-3 (Mm
00484683_m1), IL-1b (Mm 00434228_m1), IL-4 (Mm 00445259_m1),
IL-5 (Mm 00439646_m1), IL-10 (Mm 00439616_m1), IL-12p40 (Mm
00434176_m1), IL-12p35 (Mm 434165_m1), IL-13 (Mm 434204_m1),
IFNg (Mm 00801778_m1), Langerin (Mm00523545_m1), T-bet
(Mm00450960_m1), and TNFa (Mm 00443258_m1). The reactions
were performed in 12.5 ml using an universal PCR Master Mix
without UNG (Eurogentec, Germany). Expression of target genes
were relatively quantified as fold expression of the housekeeping
gene, HPRT.
Histology and Immunohistochemistry
For histological analysis half an ear was embedded in paraffin and
cut in 6mm thick sections (Cryostat CM3050S, Leica Microsystems,
Germany). Before staining, sections were deparaffinized. For
demonstrating morphologic changes and eosinophil infiltration,
sections were stained with hematoxylin (Merck) and 0.5% eosin
(Sigma; hematoxylin and eosin staining). For mast cells detection,
acidified toluidine blue staining (Merck) was performed.
For immunohistochemistry, half an ear was embedded in freezing
medium (Leica, Germany), cut in 4mm thick sections (Cryostat
CM3050S, Leica Microsystems, Germany), and fixed with acetone.
Nonspecific activity for peroxidase staining was blocked with H2O2
(Merck). Nonspecific binding sites were blocked with goat serum
(DakoCytomation, Germany). Monoclonal rat antibodies against
mouse MHCII (I-Ad) (clone M5/114.15.2), CD4 (H129.19), or CD8
(53-6.7; BD Bioscience, Germany) were used for characterization of
infiltrating immune cells by indirect staining with a biotinylated goat
anti-rat secondary antibody (BD Bioscience, Germany). Labeled
cells were visualized with horseradish peroxidase conjugated with
streptavidin (DakoCytomation). Sections were counterstained with
hematoxylin (Sigma). Pictures were taken using microscope Ax-
ioplan (Carl Zeiss, Germany), camera Spot Insight Color (Visitron
Systems, Germany), and software Meta Vue 6.1 (Visitron Systems
Universal Imaging Corporation, UK).
Flowcytometric analysis of T cells in auricular lymph nodes
Suspensions of auricular lymph node cells were prepared by using a
70 mm cell strainer (BD Bioscience). Cells were stained with
fluorescein isothiocyanate, phycoerythrin, peridin-chlorophyll-pro-
tein cy-chrom 5 and allophycocyanine-conjugated rat antibodies
recognizing mouse CD3 (clone 145-2C11), CD4 (RM4-5), CD25
(3C7), CD45RB (H129.19), CD49d (R1-2), CD62L (MEL-14), CD69
(H1.2F3), and MHCII (I-Ad; clone M5/114.15.2; BD Bioscience).
Samples were analyzed with FACSCalibur flowcytometer and
CellQuestPro software (BD Bioscience).
Statistical analysis
Unless otherwise noted, data are given as mean±standard deviation
(SD) of 10 samples. Statistical significance for the difference between
TMA and the respective solvent group (symbol: ), the difference
between TMA and treatment group (þ ) as well as the difference
between the TMA groups (#) among the three models was estimated
with Mann–Whitney U-test after proving significance in Kruskal–-
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Wallis test. An error probability (P) of less than 0.05 was considered
as significant. Percentage values given for treatment groups exhibit
the percent inhibition of inflammation in the treatment group
compared to the increase of inflammation from solvent to the TMA
group (100%).
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